Ceftazidime/avibactam-based versus polymyxin B-based therapeutic regimens for the treatment of carbapenem-resistant Klebsiella pneumoniae infection in critically ill patients: a retrospective cohort study

Guanhao Zheng[1,2†], Jiaqi Cai[3†*], Liang Zhang[4], Dayu Chen[5], Linyu Wang[6], Yusi Qiu[7], Han Deng[8], Hao Bai[9], Xiaolan Bian[1*], Juan He[1*]

Authors' information

1. Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

2. Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

3. Department of Clinical Laboratory, Kunshan Hospital Affiliated to Nanjing University of Chinese Medicine, Kunshan, China.

4. Department of Pharmacy, Huashan Hospital Affiliated to Fudan University, Shanghai, China.

5. Department of Pharmacy, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

6. Department of Pharmacy, The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.

7. Department of Pharmacy, Guigang People's Hospital, Guigang, China.

8. Department of International Medical Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.

9. Department of pharmacy, Chongqing University Cancer Hospital, Chongqing, China.

† These authors have contributed equally to this work and share first authorship.

* Correspondence should be addressed to ① Juan He, Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China, E-mail: hejuanwin@126.com; ② Xiao-lan Bian, Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China, E-mail: bxl70029@163.com.

Table S1. Antimicrobial susceptibility characteristics of *Klebsiella pneumoniae* isolates.

Antimicrobial agent	MIC range	S[a] (%)	I[b](%)	R[c] (%)
CAZ/AVI	<20 mm–>21 mm	96.3	N/A[d]	3.7
Colistin	0.125–0.5 μg/ml	100	N/A	0
Meropenem	≥16 μg/ml	0	0	100
Imipenem	≥16 μg/ml	1.2	1.8	97.0
Tigecycline	≤0.5 μg/ml	94.5	N/A	5.5
Amikacin	≤16–≥64 μg/ml	17.1	6.1	76.8

[a]*S = Susceptible.*

[b]*I = Intermediate.*

[c]*R = Resistant.*

[d]*N/A = Not applicable.*

Table S2. Antimicrobial treatment options for patients receiving CAZ/AVI-based or PMB-based therapeutic regimens

Antimicrobial treatment option	CAZ/AVI group			PMB group		
	n = 82	30-day microbiological eradication	30-day mortality	n = 82	30-day microbiological eradication	30-day mortality
Monotherapy	33	22 (66.7)	17 (51.5)	22	8 (36.4)	16 (69.6)
Combination therapy	49	44 (89.8)	12 (24.5)	60	19 (31.7)	41 (68.3)
Carbapenems	17	14 (82.4)	5 (29.4)	19	6 (31.6)	11 (57.9)
Tigecycline	11	11 (100)	3 (27.3)	11	4 (36.4)	8 (72.7)
Amikacin	11	11 (100)	1 (9.1)	15	7 (46.7)	11 (73.3)
Fosfomycin	7	5 (71.4)	3 (42.9)	10	0 (0)	9 (90)
Aztreonam	2	2 (100)	0 (0)	0	-	-
Other Drugs	1	1 (100)	0 (0)	5	2 (40)	2 (40)
Minocycline	1	1 (100)	0 (0)	3	1 (33.3)	1 (33.3)
Moxifloxacin	0	-	-	1	1 (100)	0 (0)
SMZ/TMP[a]	0	-	-	1	0 (0)	1 (100)

[a]*SMZ/TMP = sulfamethoxazole/trimethoprim.*

Table S3. Comparison of safety between CAZ/AVI group and PMB group with different types of laboratory parameters.

Group	Laboratory parameters	Before Treatment	After Treatment	*P*-value
CAZ/AVI	ALT (U/L)	23 (14-30.3)	28.5 (17.8-45)	<0.001

	AST (U/L)	29.5 (21.5-44.3)	34 (22.5-73.8)	0.035
	TBil (μmol/L)	15.9 (12.7-21.3)	17.5 (10.5-27.7)	0.487
	CrCl (mL/min)	76.7 (46.4-119.8)	80.0 (41.6-120.7)	0.310
	BUN (mmol/L)	8.6 (6.1-13.1)	11.9 (6.3-26.0)	0.013
	APTT (s)	32.5 (28.9-39.0)	32.2 (28.1-36.9)	0.240
	PT (s)	13.6 (12.7-15.5)	14.2 (12.3-17.2)	0.085
	Fib (g/L)	2.8 (2.1-3.6)	3.3 (2.3-4.7)	0.112
PMB	ALT (U/L)	17 (10-41)	19 (12.5-34)	0.683
	AST (U/L)	28 (18.5-56)	28 (19-69.5)	0.431
	TBil (μmol/L)	14.8 (11.3-25.7)	18.4 (11.1-46.1)	0.062
	CrCl (mL/min)	56.8 (39.0-95.1)	48.3 (30.9-70.6)	<0.001
	BUN (mmol/L)	13.4 (7.3-26.0)	7.2 (4.1-11.5)	<0.001
	APTT (s)	31.0 (28.3-34.3)	32.2 (28.7-35.5)	0.482
	PT (s)	13.4 (12.2-15.3)	13.8 (12.1-16.7)	0.235
	Fib (g/L)	3.5 (2.8-4.4)	3.6 (3.0-4.4)	0.434

Statistical methods: Wilcoxon rank sum test